4//SEC Filing
Kalif Eliyahu Sharon 4
Accession 0000950170-25-031946
CIK 0000818686other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 4:02 PM ET
Size
9.4 KB
Accession
0000950170-25-031946
Insider Transaction Report
Form 4
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
Transactions
- Sale
Ordinary Shares
2025-02-28$16.21/sh−55,750$903,462→ 147,941 total - Exercise/Conversion
Ordinary Shares
2025-03-03+49,800→ 197,741 total - Exercise/Conversion
Restricted Share Units
2025-03-03−49,800→ 99,602 total→ Ordinary Shares (49,800 underlying)
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2024.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.23, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F5]Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024 and March 3, 2025, 49,800 vesting on March 3, 2026, and 49,802 vesting on March 3, 2027.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001798443
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 4:02 PM ET
- Size
- 9.4 KB